Colin Thalhofer
YOU?
Author Swipe
View article: CD39+CD103+ selected CD8+ tumor infiltrating lymphocytes for the treatment of solid tumors 3905
CD39+CD103+ selected CD8+ tumor infiltrating lymphocytes for the treatment of solid tumors 3905 Open
Description CD39+ CD103 + (double positive, DP) CD8+ T cells are primarily found in solid tumors and are enriched for tumor-reactive cells. These cells exhibit an exhausted phenotype characterized by elevated expression of CD39, PD-1, CTLA…
View article: Utilizing CD39 and CD103 to identify tumor-reactive TCRs and transducing them into T cells with no tumor reactivity leads to tumor killing in-vitro 9326
Utilizing CD39 and CD103 to identify tumor-reactive TCRs and transducing them into T cells with no tumor reactivity leads to tumor killing in-vitro 9326 Open
Description CD8+ tumor infiltrating lymphocytes (TIL) positive for CD39 and CD103 are enriched for tumor reactivity/killing, while TIL derived from tumors that are negative for CD39 and CD103 (double negative, DN) have low specificity/kill…
View article: 592 Phase I study: CD39 <sup>+</sup> CD103 <sup>+</sup> CD8 <sup>+</sup> selected TIL therapy (AGX-148) demonstrates clinical activity in patients with metastatic solid tumors
592 Phase I study: CD39 <sup>+</sup> CD103 <sup>+</sup> CD8 <sup>+</sup> selected TIL therapy (AGX-148) demonstrates clinical activity in patients with metastatic solid tumors Open
View article: 409 Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYL<sup>TM</sup> PH-762
409 Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYL<sup>TM</sup> PH-762 Open
Background Adoptive Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) can induce durable clinical responses in a percentage of patients with melanoma, however, the efficacy of standard TIL therapy (Bulk TILs) can be limited. We …
View article: 165 Generating enhanced tumor infiltrating lymphocytes through microfluidic cell squeezing
165 Generating enhanced tumor infiltrating lymphocytes through microfluidic cell squeezing Open
Background Tumor Infiltrating Lymphocyte (TIL) therapies have shown significant solid tumor activity in patients, but current TIL compositions require patient lymphodepletion and high dose IL-2 after cell infusion to support clinical activ…
View article: 172 Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM)
172 Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM) Open
Background Tumor Infiltrating Lymphocyte (TIL) therapy has proven effective for patients with stage IV melanoma, however there are critical issues that can limit the efficacy of standard TIL therapy across a wide range of different maligna…
View article: OX40, PD‐1 and CTLA‐4 are selectively expressed on tumor‐infiltrating T cells in head and neck cancer
OX40, PD‐1 and CTLA‐4 are selectively expressed on tumor‐infiltrating T cells in head and neck cancer Open
The tumor microenvironment of squamous cell carcinoma of the head and neck (SCCHN) has been shown to be immune suppressive. Therefore, strategies aimed at overcoming this issue could have a positive therapeutic impact. Hence, we investigat…
View article: Infection and Activation of Human Neutrophils with Fluorescent Leishmania infantum
Infection and Activation of Human Neutrophils with Fluorescent Leishmania infantum Open
Neutrophils (PMNs) are recruited in high numbers to sites of host infection by the protozoan parasites of the genus Leishmania. Although PMNs are capable of phagocytizing Leishmania parasites and are potent producers of anti-microbial comp…